AU2001223488A1 - Activators of peroxisome proliferator-activated alpha and beta receptors as medicaments for treating skin disorders having immunological causes - Google Patents

Activators of peroxisome proliferator-activated alpha and beta receptors as medicaments for treating skin disorders having immunological causes

Info

Publication number
AU2001223488A1
AU2001223488A1 AU2001223488A AU2348801A AU2001223488A1 AU 2001223488 A1 AU2001223488 A1 AU 2001223488A1 AU 2001223488 A AU2001223488 A AU 2001223488A AU 2348801 A AU2348801 A AU 2348801A AU 2001223488 A1 AU2001223488 A1 AU 2001223488A1
Authority
AU
Australia
Prior art keywords
activators
medicaments
skin disorders
peroxisome proliferator
treating skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001223488A
Inventor
August Bernd
Stefan Kippenberger
Stefan M. Loitsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phenion GmbH and Co KG
Original Assignee
Phenion GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenion GmbH and Co KG filed Critical Phenion GmbH and Co KG
Publication of AU2001223488A1 publication Critical patent/AU2001223488A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001223488A 2000-11-09 2000-11-09 Activators of peroxisome proliferator-activated alpha and beta receptors as medicaments for treating skin disorders having immunological causes Abandoned AU2001223488A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DE2000/003955 WO2002038150A1 (en) 2000-11-09 2000-11-09 ACTIVATORS OF PEROXISOME PROLIFERATOR-ACTIVATED α AND β RECEPTORS AS MEDICAMENTS FOR TREATING SKIN DISORDERS HAVING IMMUNOLOGICAL CAUSES

Publications (1)

Publication Number Publication Date
AU2001223488A1 true AU2001223488A1 (en) 2002-05-21

Family

ID=5648009

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001223488A Abandoned AU2001223488A1 (en) 2000-11-09 2000-11-09 Activators of peroxisome proliferator-activated alpha and beta receptors as medicaments for treating skin disorders having immunological causes

Country Status (4)

Country Link
EP (1) EP1331934B1 (en)
AU (1) AU2001223488A1 (en)
DE (1) DE50012500D1 (en)
WO (1) WO2002038150A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1742626A2 (en) * 2004-04-23 2007-01-17 The Regents of The University of California Compounds and methods for treating non-inflammatory pain using pparalpha agonists
DE102004022253A1 (en) * 2004-05-04 2005-12-08 Phenion Gmbh & Co. Kg Use of pirinixic acid and its salts for the treatment of chronic inflammatory diseases
DE102007020554A1 (en) 2007-04-27 2008-10-30 Henkel Ag & Co. Kgaa Nucleic acid-containing cosmetic and / or pharmaceutical preparations for the treatment of epithelial covering tissue
DE102007044093A1 (en) 2007-09-14 2009-03-19 Phenion Gmbh & Co. Kg Nucleic acid-containing cosmetic and / or pharmaceutical preparations for the induction of antimicrobial peptides in epithelial cover tissues
ES2397889B1 (en) 2011-03-25 2014-02-07 Lipotec, S.A. MODULATING PEPTIDES OF PGC-1 Alpha.
DE202017105254U1 (en) 2017-08-31 2017-09-19 Jassen GmbH Long-term transparent cosmetic preparations
CN108992435A (en) * 2018-07-10 2018-12-14 中国人民解放军第四军医大学 Fenofibrate is preparing the application in Changes of Radiation Damaged Skin prevention and treatment externally applied drug
IT202000027489A1 (en) * 2020-11-17 2022-05-17 Mauro Michele Maria Picardo Selective activators of peroxisome proliferator-activated receptors (PPARs) for the treatment of vitiligo
DE202021102468U1 (en) 2021-05-06 2021-06-28 ForMe Cosmetics GmbH i.G. Multi-chamber system for storing and mixing components of cosmetic formulations
DE102021111896A1 (en) 2021-05-06 2022-11-10 ForMe Cosmetics GmbH i.G. Multi-chamber system for storing and mixing components of cosmetic formulations
DE202021106186U1 (en) 2021-11-11 2021-12-14 Jassen GmbH Cosmetic preparation for care and treatment of periocular skin
DE102021129474A1 (en) 2021-11-11 2023-05-11 Jassen GmbH Cosmetic preparation for care and treatment of periocular skin
DE102021130541A1 (en) 2021-11-22 2023-05-25 Jassen GmbH Cosmetic preparation for intensive care and treatment of facial skin
DE202021106362U1 (en) 2021-11-22 2021-12-14 Jassen GmbH Cosmetic preparation for intensive care and treatment of facial skin
DE102021130543A1 (en) 2021-11-22 2023-05-25 Jassen GmbH Cosmetic preparation for the care and treatment of facial skin
DE202021106363U1 (en) 2021-11-22 2021-12-15 Jassen GmbH Cosmetic preparation for the care and treatment of facial skin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060515A (en) * 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
AU5928898A (en) * 1997-01-24 1998-08-18 Regents Of The University Of California, The Use of fxr, pparalpha and lxralpha activators to restore barrier function, promote epidermal differentiation and inhibit proliferation
FR2773075B1 (en) * 1997-12-31 2000-05-05 Cird Galderma USE OF PPAR-GAMMA ACTIVATORS IN DERMATOLOGY
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
DE10053003A1 (en) * 1999-10-19 2001-06-28 Univ Jw Goethe Frankfurt Main Treatment of immunologically induced skin disorders, skin aging or neuropathy, comprises using peroxisome-proliferator activated receptor, alpha, beta activators such as pirinixic acid

Also Published As

Publication number Publication date
WO2002038150A1 (en) 2002-05-16
DE50012500D1 (en) 2006-05-18
EP1331934A1 (en) 2003-08-06
EP1331934B1 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
AU2001223488A1 (en) Activators of peroxisome proliferator-activated alpha and beta receptors as medicaments for treating skin disorders having immunological causes
HUP9801599A3 (en) Use of imidazolin derivatives having alfa1l agonist effect for producing pharmaceutical compositions for treatment of incontinence, novel imidazolin derivatives and process for producing them
AU2003300939A1 (en) Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
IL127943A (en) Pharmaceutical and cosmetic compositions for the treatment of skin disorders
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
IL122733A0 (en) Pharmaceutical compositions for use in the treatment of allergic asthma
IL147440A0 (en) Composition for treatment of external secretion disorders
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
AU6919100A (en) Compositions including modafinil for treatment of eating disorders and for appetite stimulation
AU7067200A (en) Skin care compositions and treatments
AU2003223601A1 (en) ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN Beta 4
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
AU2001275707A1 (en) Use of panaxatriol for stimulation angiogenesis
HUP0104963A3 (en) Compositions for the treatment of skin diseases
HUT60438A (en) Application of inhaled non-steroid inflammation reducers for potentiation of antireactive, antiasthmatic effect of inhaled henle's loop-diuretics
AU7106300A (en) Treatment of skin disorders
EP1455780A4 (en) Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
AU3922900A (en) Use of (valeriana) for the treatment of restless leg syndrome and related disorders
AU2003282626A1 (en) Use of flavonoid for the treatment of overweight and the reduction of the mammalian appetite
AU3263795A (en) Medicament for treatment or prophylaxis of incontinence
HUP0001913A3 (en) Use of pramipexole for the preparation of pharmaceutical compositions treating restless legs syndrome
AU7378400A (en) Peroxisome proliferator-activated receptor alpha and disorders of lipid metabolism
AU1022501A (en) Use of compositions for the caring treatment of the skin